Acuitive Technologies, Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market CITREPORE, a unique synthetic bioactive bone void filler, using ...

CITREPORE is an exciting addition to Acuitive's product portfolio and provides a unique opportunity for its use in numerous ...

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

A fter roasting your Thanksgiving turkey to golden brown perfection, there's only one step that stands between you and a ...

Several epidemiologic studies associate bone-resorbing chronic inflammatory conditions with increased risk of atherosclerotic heart disease. These include post-menopausal osteoporosis, spinal cord ...